


RNA therapy for neurodegenerative, cardiac, and pulmonary disease

ASO therapeutic targeting MEG3 for neurodegenerative diseases, including Alzheimer's.

MEG3 is a long non-coding RNA, implicated in Neurodegenerative, cardiac, and pulmonary disease. In Alzheimer's disease a knockdown model was shown to have reduced necroptosis. The technology is oligonucleotide-based therapies to target the transcript.

Applications: Therapeutics, RNA therapies, Neurodegenerative diseases



Features	Benefits
Targets MEG3	Implicated in neurodegenerative, cardiac, and pulmonary disease
Can reduce MEG3 expression to 5% or lower	Optimise expression level
Efficacy in gapmer and siRNA formats	Multiple approaches to suit disease and technology
Reduces necroptosis	Targets main driver of AD pathology

Patented and Available for

- Co-development

- Consulting
 - Licensing
-

To find out more, contact enquiries@innovation.ox.ac.uk and quote the project number.

The above information is provided 'as is' without conditions or warranties. Oxford University Innovation makes no representation and gives no warranty that it is the owner of the intellectual property rights in the technology described. © Oxford University Innovation Ltd 2026, Buxton Court, 3 West Way, Oxford, OX2 0JB.